Monlunabant

Monlunabant ((S) -MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with Ki of 0.3 nM and 613 nM[1].

Product Specifications

CAS Number

[2712480-46-9]

Product Name Alternative

(S) -MRI-1891; INV-202

UNSPSC

12352005

Target

Arrestin; Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/monlunabant.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(N/C(N1N=C(C2=CC=C(C=C2)Cl)[C@@H](C3=CC=CC=C3)C1)=N/C(NC(C)=O)=N)(C4=CC=C(C=C4)C(F)(F)F)=O

Molecular Formula

C26H22ClF3N6O3S

Molecular Weight

591.00

References & Citations

[1]Liu Z, et al., Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist. ACS Pharmacol Transl Sci. 2021 Apr 8;4 (3) :1175-1187.|[2]Ghosh A, et al., A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets. Eur J Pharmacol. 2023 Apr 5;944:175589